Institutional Placement and proposed Share Purchase Plan SPP
Released
Released
Announcement PDF
ASX Announcement
18 July 2023
Institutional Placement and proposed Share Purchase Plan
Key Highlights:
•
$8.35 million Placement to sophisticated and institutional investors at $0.05 per share
•
Antisense also intends to launch a SPP in the coming days
•
The funds raised will enable Antisense to advance its ongoing international phase IIb study of
ATL1102 in Duchenne muscular dystrophy, and also be used for working capital purposes
Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY | FSE:AWY] (Antisense or Company) is
pleased to announce that it has raised $8.35 million under an institutional placement (Placement) of
new ordinary shares in the Company (New Shares). The raise was well supported with an existing
institutional shareholder as cornerstone investor subscribing for $4 million worth of New Shares under
the Placement.
The Company also intends to undertake a share purchase plan (SPP) for eligible existing shareholders,
to provide an opportunity for them to participate, the details of which will be shared within the
placement completion and allotment announcement (21 July 2023).
Placement
Under the Placement, Antisense will issue 166.99 million New Shares in the Company at $0.05 per New
Share, which represents a discount of approximately 23% to the last closing price of the Company's
ordinary shares prior to the trading halt on 13 July 2023. New Shares issued under the Placement will
be issued under the Company’s placement capacity under ASX Listing Rule 7.1 and 7.1A. Specifically,
the Company will issue 100.09 million New Shares under the Company’s Listing Rule 7.1 capacity, and
66.90 million New Shares under its Listing Rule 7.1A capacity.
The New Shares issued under the Placement will rank equally with the Company’s existing fully paid
ordinary shares. The Company will apply for quotation of the New Shares on ASX on 24 July 2023.
“We are delighted by and appreciative of the strong support from our existing institutional supporters
and sophisticated investors” said Antisense Chair Dr. Charmaine Gittleson. “In particular, we are
pleased to see new quality institutions and specialty funds with an interest in Biotech coming onto the
registry. This equity raising strengthens our balance sheet. The new funds will allow us to continue the
development of our clinical programs, in particular funding the ongoing international Phase IIb Clinical
Trial program for ATL1102 in Duchenne muscular dystrophy, as well as for ongoing working capital.
The next 12-18 months are an exciting and busy time with results from the mdx DMD mouse study
anticipated in July ‘23, the Limb Girdle R2 Dystrophy animal study in August ‘23, the 9-month chronic
toxicology study around May ’24 and the clinical study primary endpoint readout anticipated July ’24”.
Morgans Corporate Limited acted as Lead Manager to the Placement.
Key dates for the Placement are set out in the Key Dates section below.
______________________________________________________________________________________________________
LEVEL 1, 14 WALLACE AVENUE, TOORAK VIC 3142 AUSTRALIA TEL . +61 3 9827 8999 FAX +61 3 9859 7701 WEB WWW.ANTISENSE.COM.AU
ANTISENSE THERAPEUTICS LIMITED - ABN 41 095 060 745
ME_211755895_1
Page 1 of 2
Intention to undertake SPP
The Company also proposes to undertake an SPP for shareholders with a registered address in Australia
and New Zealand to provide an opportunity for existing shareholders to participate.
The Antisense Board of Directors reserves absolute discretion regarding the amount raised under the
SPP and will determine the timetable for launch and other key details of the SPP in due course.
Key Dates for the Placement
Event
Date*
(Australian Eastern
Standard Time)
Trading Halt lifted, announcement of Completion of Placement
Tuesday, 18 July 2023
Settlement of New Shares under the Placement
Friday, 21 July 2023
Allotment and commencement of trading of New Shares under the
Placement
Monday, 24 July 2023
The timetable is indicative only and subject to change. The Company reserves the right to amend the
dates at its discretion and without notice, subject to the ASX Listing Rules and the Corporations Act
2001 (Cth).
For more information please contact:
Antisense Therapeutics
Charmaine Gittleson
Executive Chair
+61 (0)3 9827 8999
www.antisense.com.au
Investment Enquiries
Gennadi Koutchin
XEC Partners
gkoutchin@xecpartners.com.au
1300 932 037
US/European IR & Media
Laine Yonker/Joe Green
Edison Investor Relations
lyonker@edisongroup.com
+1 646-653-7035
This announcement has been authorised for release by the Executive Chair.
About Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] is a publicly listed biotechnology
company developing and commercializing antisense pharmaceuticals for rare diseases with significant unmet medical need.
The company’s lead program is ATL1102, an antisense inhibitor of the CD49d receptor, which is currently the subject of an
ongoing international Phase IIb trial for Duchenne Muscular Dystrophy. The drug previously reported highly promising results
from an exploratory Phase II trial.
______________________________________________________________________________________________________
LEVEL 1, 14 WALLACE AVENUE, TOORAK VIC 3142 AUSTRALIA TEL . +61 3 9827 8999 FAX +61 3 9859 7701 WEB WWW.ANTISENSE.COM.AU
ANTISENSE THERAPEUTICS LIMITED - ABN 41 095 060 745
ME_211755895_1
Page 2 of 2
Share your feedback
Discover